Spruce Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $4.9M | $10.1M | $0 | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $19.5M | $46.4M | $49.4M | $35.2M | $30.7M | $23.9M | $10.8M |
| SG&A Expense | — | $17.0M | $14.6M | $12.7M | $12.1M | $11.4M | $5.6M | $2.3M |
| Operating Income | — | $-36.5M | $-56.2M | $-52.0M | $-47.3M | $-42.1M | $-29.4M | $-13.1M |
| Operating Margin | — | — | -1,143.4% | -515.3% | — | — | — | — |
| Interest Expense | — | $90.0K | $307.0K | $483.0K | $420.0K | $345.0K | $323.0K | $65.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-39.0M | $-53.0M | $-47.9M | $-46.2M | $-42.3M | $-29.5M | $-13.1M |
| Net Margin | — | — | -1,079.9% | -475.0% | — | — | — | — |
| EPS (Basic) | — | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 | $-4.93 | $-17.12 |
| EPS (Diluted) | — | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 | $-4.93 | $-17.12 |
| Shares Outstanding (Basic) | 1.4M | 766.6K | 550.1K | 38.5M | 23.5M | 23.4M | 23.3M | 764.4K |
| Shares Outstanding (Diluted) | 1.4M | 766.6K | 550.1K | 38.5M | 23.5M | 23.4M | 23.3M | 764.4K |
| Dividends Per Share | — | — | — | — | — | — | — | — |